×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$18.85
+0.20 (+1.07%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$18.28
$19.09
50-Day Range
$16.49
$21.27
52-Week Range
$15.91
$28.95
Volume
4,521 shs
Average Volume
346,880 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Crinetics Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
117.5% Upside
$41.00 Price Target
Short Interest
Bearish
5.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.82mentions of Crinetics Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$4.47 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.69) to ($2.81) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.20 out of 5 stars

Medical Sector

159th out of 1,428 stocks

Pharmaceutical Preparations Industry

63rd out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Crinetics Pharmaceuticals logo

About Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CRNX Stock News Headlines

How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
This Options Expert is Giving Everything Away!
Trading champion Chuck Hughes has exposed the strategies of successful traders and handing them over to new traders like you! His guide “Options Trading Made Easy” now comes with a Trade of the Day from Chuck himself to help you develop a profitable, pro-level trading account!
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
143
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$41.00
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+117.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-107,640,000.00
Pretax Margin
-2,812.00%

Debt

Sales & Book Value

Annual Sales
$1.08 million
Book Value
$6.99 per share

Miscellaneous

Free Float
50,349,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
1.26














Crinetics Pharmaceuticals Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price forecast for 2022?

6 equities research analysts have issued 12 month target prices for Crinetics Pharmaceuticals' stock. Their CRNX stock forecasts range from $35.00 to $45.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $41.00 in the next year. This suggests a possible upside of 117.5% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Crinetics Pharmaceuticals' stock price performed in 2022?

Crinetics Pharmaceuticals' stock was trading at $28.41 at the beginning of 2022. Since then, CRNX stock has decreased by 33.7% and is now trading at $18.85.
View the best growth stocks for 2022 here
.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) released its quarterly earnings data on Thursday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.17. The firm earned $3.13 million during the quarter.
View Crinetics Pharmaceuticals' earnings history
.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Dr. R. Scott Struthers Ph.D., Founder, Pres, CEO & Director (Age 60, Pay $907.11k)
  • Mr. Jeff E. Knight, Chief Operating Officer (Age 51, Pay $237.64k)
  • Dr. Stephen F. Betz Ph.D., Founder & Chief Scientific Officer (Age 56)
  • Mr. Marc J. C. Wilson, Chief Financial Officer (Age 43)
  • Ms. Garlan Adams, Gen. Counsel & Corp. Sec.
  • Ms. Adriana Cabre M.B.A., Chief HR Officer
  • Dr. Alan S. Krasner M.D., Chief Medical Officer (Age 59)
  • Mr. Kevin Capps, Head of Intellectual Property
  • Mr. James Hassard, Chief Commercial Officer (Age 56)
  • Mr. Chris Robillard M.B.A., Chief Bus. Officer

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $18.85.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals (NASDAQ:CRNX) has a market capitalization of $1.01 billion and generates $1.08 million in revenue each year. The company earns $-107,640,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 143 workers across the globe.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The official website for Crinetics Pharmaceuticals is www.crinetics.com. The company can be reached via phone at (858) 450-6464 or via email at ir@crinetics.com.

This page (NASDAQ:CRNX) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.